# US 2026/0077027 A1 · Peptide and nucleic acid methods to modulate delivery of nucleic acid structures, polypeptides, and their cargoes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077027 A1
- Document ID: US20260077027A1
- Status: Published application
- Kind: A1
- Application number: 19/105,977
- Filed: 2023-08-24
- Published: 2026-03-19
- Earliest claimed: 2022-08-25
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Niksa ROKI; Carlos CASTRO; Christopher LUCAS; Meixiao LONG; John BYRD
- Web page: https://patentgrep.com/patent/US20260077027A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6455: {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61P 37/04: Immunostimulants
- C07K 14/435: from animals; from humans
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/6025: {Nucleotides}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are methods and compositions for enhancing delivery and function of vaccine components, immunotherapy Agents, and improved delivery of nucleic acid nanostructures, nucleic acids, peptides, polypeptides, and other types of cargoes. These methods and compositions utilize design components suitable for rapid and cost-effective manufacturing, and are designed to exclusively use the process of self-assembly to form nanotherapeutics requiring no purification in many instances.

## Claims

### Claim 1

A nanoparticle comprising i) a base nanostructure formed from a plurality of nucleic acid scaffold strands and a plurality of nucleic acid staple strands assembled into a geometry, ii) a branched oligonucleotide dendrimer,
wherein the base nanostructure is a non-branching and non-dendrimer nucleic acid nanostructure,
wherein the base nanostructure comprises one or more first single stranded nucleic acid oligonucleotide attachment arms configured to directly bind to a first complementary nucleic acid oligonucleotide strands, and
wherein the branched oligonucleotide dendrimer that has self-assembled by nucleic acid oligonucleotide complementarity and non-complementarity that comprises i) a plurality of second single stranded nucleic acid oligonucleotide attachment arms configured to bind to second complementary nucleic acid oligonucleotide strand, and ii) at least one of the first complementary nucleic acid oligonucleotide strands.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, further comprising a peptide attached to the base nanostructure and/or the branched oligonucleotide dendrimer by electrostatic interaction.

### Claim 3 (depends on 2)

The nanoparticle of claim 2, wherein the peptide comprises i) a peptide antigen sequence, cell penetrating peptide sequence, or ligand-targeted peptide sequence, and ii) a charged peptide sequence configured to attach to the nanoparticle by electrostatic interactions.

### Claim 4 (depends on 3)

The nanoparticle of claim 3, wherein the charged peptide sequence comprises at least 5, 6, 7, 8, 9, or 10 contiguous positively charged amino acids.

### Claim 5 (depends on 2, 3, 4)

The nanostructure of any one of claims 2 to 4, wherein peptide comprises the amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 1).

### Claim 6 (depends on 2, 3, 4, 5)

The nanoparticle of any one of claims 2 to 5, comprising at least 1,000 peptides attached to the base nanostructure and/or the branched oligonucleotide dendrimer.

### Claim 7 (depends on 2, 3, 4, 5)

The nanoparticle of any one of claims 2 to 5, comprising at least 50, 60, 70, 80, 90, 100 nM peptide.

### Claim 8 (depends on 1)

The nanoparticle of claim 1, consisting of nucleic acids and ions.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The nanoparticle of any one of claims 1 to 8, further comprising a nucleic acid-based adjuvants.

### Claim 10 (depends on 9)

The nanoparticle of claim 9, wherein the nucleic acid-based adjuvant is a CpG adjuvant.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nanoparticle of any one of claims 1 to 10, wherein the base nanostructure is completely or partially assembled using DNA or RNA origami to direct and organize the origin of nucleic acid-made branches on or within the base nanostructure using exclusively nucleic acids material and the 3D nature of the base nanostructure and branches themselves, while nucleic acid-based branches further control the topography and density of the structure, including based on the length of branching units and the branching density or frequency, including the topography, density, and spacing of attachment sites for various functions and various molecules of interest.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The nanoparticle of any one of claims 1 to 11, wherein each branched oligonucleotide dendrimer comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 second single stranded nucleic acid oligonucleotide attachment arms.

### Claim 13

The nanoparticle of any one of claims to 1 to 10 encapsulated in alginate capsules.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating a tumor in a subject, comprising administering the nanoparticle of any one of claims 1 to 13 into the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the nanoparticle is administered intravenously or intratumorally.

### Claim 16

A branched nucleic acid-made dendrimer nanostructure electrostatically complexed with peptides containing amino acids with amine groups, guanidine groups, or positive charges, wherein the branched nucleic acid dendrimer nanostructure provides an electrostatic attachment modality with nucleic acid binding peptides through branching arms that collapse to complex with the nucleic acid binding peptides, wherein at least two or more distinct locations distanced by more than 20 bases apart on the nucleic acid nanostructure are electrostatically contacting and binding the peptides simultaneously.

### Claim 17

A method for stimulating anti-tumoral effect in a tumor of a subject, comprising injecting into the tumor alginate capsules containing a peptide having the amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 1) complexed with a nucleic acid CpG adjuvant or nucleic acid nanostructure containing an adjuvant.

### Claim 18 (depends on 17)

The method of claim 17, wherein the peptide further comprises an antigen sequence.

### Claim 19

A fusion protein comprising a peptide having the amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO:1) fused to a peptide antigen sequence, cell penetrating peptide sequence, or ligand-targeted peptide sequence.

### Claim 20

A method of protecting branched nucleic acid dendrimer nanostructure via electrostatic complexation with peptides.

### Claim 21 (depends on 20)

The method of claim 20, wherein the peptides comprise the amino acid sequence (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO:1).

### Claim 22

A method of mediating cytosolic delivery of a nucleic acid nanostructure, comprising electrostatically complexing the nucleic acid nanostructures with a peptide having the amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO:1).

### Claim 23

A method of enhancing cytosolic delivery of nucleic acid nanostructures, comprising decorating the nucleic acid nanostructures with a branched nucleic acid structure layer.

### Claim 24 (depends on 22)

The method of claim 22, further comprising complexing the nucleic acid nanostructures with a peptide having the amino acid sequence (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO:1).

### Claim 25 (depends on 1)

The nanoparticle of claim 1, wherein the peptide (e.g., peptide antigen) comprises cell penetrating peptides and/or antimicrobial peptides at the N- and/or C-terminus for tuning the peptide electrostatic attachment to nucleic acid nanostructures, increased cell uptake and cytosolic delivery, and further may contain at least one peptide cleavage site (e.g., cathepsin cleavage site, furin cleavage site, etc.), and/or at least one immunoproteasome processing site for peptide processing containing the amino acid sequence (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO:1).

### Claim 26 (depends on 1)

The nanoparticle of claim 1, wherein the at least 5, 6, 7, 8, 9, or 10 continuous positively charged amino acids are at the N-terminus of the peptide antigen.

### Claim 27 (depends on 1)

The nanoparticle of claim 1, wherein the at least 5, 6, 7, 8, 9, or 10 continuous positively charged amino acids are at the C-terminus of the peptide antigen.

### Claim 28 (depends on 1)

The nanoparticle of claim 1, wherein the positively charged amino acids are lysine or arginine amino acids.

### Claim 29 (depends on 1)

The nanoparticle of claim 1, wherein the peptide antigen comprises at least contiguous lysine amino acids.

### Claim 30 (depends on 1)

The nanoparticle of claim 1, wherein the peptide antigen comprises at least contiguous arginine amino acids.

### Claim 31 (depends on 1)

The nanoparticle of claim 1, comprising at least 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 peptides per nm2.

### Claim 32 (depends on 1)

The nanoparticle of claim 1, wherein each of the plurality of scaffold strands are 300 to 15,000 nucleotides in length.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The formulation pertaining to any one of claims 1 to 32, wherein the peptide antigen comprises a viral antigen.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The formulation pertaining to any one of claims 1 to 32, wherein the peptide antigen comprises a tumor specific neoantigen and/or tumor associated antigen.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The formulation pertaining to any one of claims 1 to 34, wherein the nucleic acid nanostructure comprises one or more first single stranded nucleic acid oligonucleotide attachment arms configured to bind to a first complementary nucleic acid oligonucleotide strands.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The formulation pertaining to any one of claims 1 to 35, further comprising a plurality of nucleic acid adjuvant molecules conjugated to first complementary nucleic acid oligonucleotide strands or second complementary nucleic acid oligonucleotide strands.

### Claim 37 (depends on 36)

The formulation of claim 36, wherein the plurality of nucleic acid adjuvant molecules are CpG molecules.

### Claim 38 (depends on 1, 2)

A nanoparticle of any one of claims 1 and 2, wherein the base nucleic acid nanostructure comprises a single or multiple cavities, wherein the one or more first single stranded oligonucleotide attachment arms containing branched nucleic acid dendrimers are positioned inside and/or outside of the cavity, or within the base nucleic acid nanostructure.

### Claim 39 (depends on 1, 2)

A nanoparticle of any one of claims 1 and 2, further comprising one or more targeting ligands conjugated to the first complementary nucleic acid oligonucleotide strands or second complementary nucleic acid oligonucleotide strands.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method for vaccinating a subject, comprising administering to the subject the vaccine device of any one of claims 1 to 39.

### Claim 41

A non-DNA origami nucleic acid nanostructure formed from a nucleic acid material and optionally therapeutic, targeting, sensing, imaging, detection, and building materials (e.g., phospholipids), comprising a peptide of interest, which is extended via peptide bond (i.e., amide bond) synthesis to contain additional peptide sequence/s that allow attachment of the peptide sequences of interest to the nucleic acid polymers of the nanoparticle by electrostatic or other interactions.

### Claim 42 (depends on 41)

The nanoparticle of claim 41, wherein the peptide sequence of interest can be polypeptide or protein.

### Claim 43

A nucleic acid dendrimer nanostructure that is made by self-assembly of unique predefined sequences at predefined molar ratios in one step (i.e., one pot synthesis) in the presence of only 1× phosphate buffered saline and require no purification procedures after the self-assembly process.

### Claim 44

A nucleic acid dendrimer nanostructure that is made by self-assembly of unique predefined sequences that do not require oligonucleotide purification such as HPLC or PAGE before self-assembly process and are assembled at predefined molar ratios in one step (i.e., one pot synthesis) in the presence of only 1× phosphate buffered saline and require no purification procedures after the self-assembly process.

### Claim 45

A nucleic acid nanovaccine delivery platform that can directly incorporate FDA approved oligonucleotide adjuvants (e.g., CpG) by direct attachment to the nucleic acid structure, without the need for modification of oligonucleotide adjuvant, while preserving adjuvant function and potency.

### Claim 46 (depends on 1)

The nanoparticle of claim 1, wherein the peptide comprises 1 to 5 contiguous positively charged amino acids.

### Claim 47 (depends on 1)

The nanoparticle of claim 1, wherein the peptide comprises 1 to 3 contiguous positively charged amino acids.

### Claim 48

A nucleic acid structure, comprising a nucleic acid origami nanostructure formed from a plurality of scaffold strands and a plurality of staple strands assembled into a geometry, wherein the nucleic acid nanostructure comprises one or more first single stranded oligonucleotide attachment arms configured to bind to a first complementary oligonucleotide strands, further comprising a branched oligonucleotide dendrimer comprising a plurality of second single stranded oligonucleotide attachment arms and at least one first complementary oligonucleotide strand, wherein the second single stranded oligonucleotide attachment arms are configured to bind to second complementary oligonucleotide strands.
